EP1855656A2 — Orally bioavailable cci-779 tablet formulations
Assigned to Wyeth LLC · Expires 2007-11-21 · 18y expired
What this patent protects
A CCI-779 oral dosage form is provided in which, after oral administration to a subject, the CCI-779 has a whole blood peak concentration (Cmax) of 5.4 ± 1.8 ng/mL and an area under the curve (AUC) of about 66 ± about 22 ng-hr/ml and the sirolimus has a Cmax of 18.7 ± 9.6 ng/mL a…
USPTO Abstract
A CCI-779 oral dosage form is provided in which, after oral administration to a subject, the CCI-779 has a whole blood peak concentration (Cmax) of 5.4 ± 1.8 ng/mL and an area under the curve (AUC) of about 66 ± about 22 ng-hr/ml and the sirolimus has a Cmax of 18.7 ± 9.6 ng/mL and an AUC of about 600 ± about 228 ng- hr/ml, for a 25 mg unit dose of CCI-779-Products containing these oral dosage forms, and methods of use thereof, are also described.
Drugs covered by this patent
- Torisel (temsirolimus) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.